Visiongain Publishes Tissue Sectioning Market Report 2021-2031
17 February 2021
Visiongain has published a new report on Tissue Sectioning Market Report 2021-2031: Forecasts by Product (Instruments, Accessories & Consumables), By Technology (Automatic, Manual), by Application (Diagnosis, Research), By End Use (Hospitals, Clinics, Diagnostic Laboratories, Research Centres). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Tissue Sectioning market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031. Rising prevalence of chronic diseases and cancers is one of the crucial factors driving demand for histopathology tests as a tissue pathology examination is of utmost importance for the diagnosis of a malignant tumor.
COVID-19 Impact on Tissue Sectioning market
The COViD-19 pandemic impact on the Tissue Sectioning Market growth is considered to be unaffected as the market is directly influenced by the spread of the cancer disease globally. The spread of pandemic is not making any negative impact on the growth of Tissue Sectioning market.
According to the latest medical research, by WHO, Cancer is revealed as one of the prominent causes of death globally. Investigation of biopsy tissues enables pathologists to detectthe cancer type, stage, and the degree to which the disease has entered healthy tissues. This has resultedinto an increased adoption of histopathology and tissue sectioning and staining instruments, in turn the tissue sectioning market growth.
The increase in attentiveness programs carry out by associations, such as National Cervical Cancer Coalition, World Health Organization (WHO), the Centres for Disease Control and Prevention (CDC), and the U.S. Preventive Services Task Force (USPSTF), for cancer screening, is a crucial factor boosting the market growth. Inventiveness taken by major market players to undertake initiatives for generating awareness about cervical and vaginal cancer screening is considered as a major growth prospect for the market.
For example, the National Health Service (NHS) provides cervical screening programs for all women between 25 and 64 years of age in the U.K. Women aged between 25 years and 49 years are mostly screened every three years, however women aged between 50 years to 64 years are screened every five years. The Norway government introduced the Norwegian Cervical Cancer Screening Programme (NCCSP) offers to screen women between 25 and 69 years, every three years.
Some of the key players profiled in the market include Thermo Fisher Scientific, Leica Biosystems Nussloch GmbH, LLS ROWIAK LaserLabSolutions GmbH, and Sakura Finetek Europe B.V., Danaher Corporation, MEDITE GmbH, SLEE medical GmbH, Boeckeler Instruments, Inc., SM Scientific Instruments Pvt. Ltd., AGD Biomedicals (P) Ltd., Amos Scientific Pty Ltd., Covance Inc., Abcam.
Thecompanies are involved in partnerships with laboratories to maintain a competitive advantage. Initiatives adopted by the key players for troubleshooting the processing issues faced by the lab technicians are expected to address the problem of under-processed tissue. The companies actively provide specific histology solutions for FFPE DNA or RNA isolation, highly applicable in research arena.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033